Knowledge Center

Ash Stevens' Dr. Stephen A. Munk, President & CEO, to Speak at Global Supplier & Partnership Management Conference

Detroit, Michigan – December 1, 2010 – Dr. Stephen A. Munk, President & CEO of Ash Stevens, Inc. (ASI), will offer his views on transforming supplier relationships from transactional to strategic at the Global Supplier & Partnership Management conference Wednesday, December 1 at 12:00 CET in Berlin, Germany.

Dr. Munk's presentation is part of the Strategies & Tactics portion of the conference, which convenes at the Kempinski Hotel Bristol. The session will highlight a comprehensive tactical approach to novel ways of managing relationships to ensure quality control, flexibility and risk mitigation.

Dr. Munk's presentation will cover the benefits of a strategic relationship; forecasting to minimize unnecessary cost and to guarantee supply; and converting forecasts into time-phased requirement schedules through the entirety of the supply chain.

About Ash Stevens, Inc.
Ash Stevens, Inc. (ASI) is a full service Contract Pharmaceutical Manufacturer offering comprehensive small-molecule drug substance development and cGMP manufacturing services. Founded in 1962 and headquartered in Detroit, Michigan, ASI has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs) for commercial clients in the Life Sciences industry developing innovator small-molecule therapeutics. ASI is a longtime provider of contract research services to the National Institutes of Health and the National Cancer Institute and has worked on many of the drugs developed through these government agencies. To date, ASI has received eleven FDA manufacturing approvals for innovator APIs, including Four Fast-Track manufacturing approvals for the active ingredients in the oncology drugs Velcade®, Vidaza®, and Clolar®. Services offered by Ash Stevens include: process development and scale-up; cGMP manufacturing; the development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities (including method development, stability studies and qualification of reference standards); and regulatory support for all phases of drug development and manufacturing. For more information, visit